Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$58.75
pos +0.21
+0.36%
Today's Range: 58.28 - 58.82 | MRK Avg Daily Volume: 9,413,100
Last Update: 07/30/15 - 2:25 PM EDT
Volume: 4,148,209
YTD Performance: 3.08%
Open: $58.62
Previous Close: $58.54
52 Week Range: $52.49 - $63.62
Oustanding Shares: 2,825,221,749
Market Cap: 162,506,755,002
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 6 6
Moderate Buy 0 0 0 0
Hold 7 7 6 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.08 2.08 2.00 2.08
Latest Dividend: 0.45
Latest Dividend Yield: 3.13%
Dividend Ex-Date: 09/11/15
Price Earnings Ratio: 12.73
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
12.73 15.00 25.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.91% -0.07% 29.81%
GROWTH 12 Mo 3 Yr CAGR
Revenue -4.10 -0.12 -0.04
Net Income 164.20 0.87 0.23
EPS 176.90 1.02 0.26
Earnings for MRK:
EBITDA 13.37B
Revenue 42.24B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.90 $0.90 $3.48 $3.83
Number of Analysts 8 7 7 12
High Estimate $0.93 $0.92 $3.52 $3.97
Low Estimate $0.86 $0.87 $3.45 $3.69
Prior Year $0.90 $0.87 $3.49 $3.48
Growth Rate (Year over Year) -0.28% 3.94% -0.37% 10.05%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

David Katz

 | Jul 30, 2015 | 11:00 AM EDT

Drugmaker has one of the best showings of earnings season.

By

David Katz

 | Jul 30, 2015 | 8:30 AM EDT

Drugmaker has one of the best showings of earnings season.

By

Bret Jensen

 | Jul 29, 2015 | 7:39 AM EDT
I'm happy as always to be standing in for Doug Kass on the Daily Diary.
By

Doug Kass

 | Jul 28, 2015 | 8:07 AM EDT
After five or six days of market declines, the S&P futures are +12 this morning -- and I'm not surprised.
By

Chris Laudani

 | Jul 28, 2015 | 8:00 AM EDT

Competition and lower earnings cloud its future.

By

Jim Cramer

 | Jul 16, 2015 | 2:51 PM EDT

They should learn to trust techs, financials.

By

Jim Cramer

 | Jul 15, 2015 | 7:07 AM EDT

These stocks will be up so high today, that many fans will say "no thanks."

By

Ophir Gottlieb

 | Jul 2, 2015 | 11:00 AM EDT

It's almost impossible to get too excited about its success.

By

Roger Arnold

 | Jun 25, 2015 | 1:46 PM EDT

As health-care stocks rally, it's time for politicians to move on.

By

Chris Laudani

 | Jun 24, 2015 | 1:00 PM EDT

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

Market is giving back some of its gains of the last two sessions. With slightly over half ...
After three straight gains, on accelerating trade, PFE is pulling back. At yesterday's...

The IMF/Greece news triggers higher bond prices, lower yields.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.